Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...
Tandem secures approval for t:slim X2 insulin pump to use with Lyumjev
Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...
drugdeliverybusiness3d
Tandem wins clearance for t:slim X2 pump with Eli Lilly fast-acting insulin in Europe
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...
drugdeliverybusiness5d
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...
Why Tandem Diabetes Care Stock Thrashed the Market Today
Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...
kalkinemedia2d
Tandem Diabetes Gains Momentum with Key EU Approval
Headlines,Tandem Diabetes Care shares saw a significant rise after a crucial EU approval for its insulin delivery system.,The ...
FierceBiotech5d
FDA clears Senseonics' 365-day Eversense CGM implant
After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...
Monthly Prescribing Reference5d
Long-Term CGM System Eversense 365 Gets FDA Clearance
Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the ...
BioWorld5d
FDA clears Senseonic’s Eversense one-year implantable CGM
The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...
HME News5d
Senseonics, Ascensia launch one-year CGM system
Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...